Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Gilles Andre Salles, MD, PhD, Myron S. Czuczman, MD, Sarit E. Assouline, MD, Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, Manish Patel, MD, Randeep Sangha, Herve Tilly, MD, Ranjana Advani, MD, Olivier Casasnovas, MD, Oliver W. Press, MD, PhD, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Franck Morschhauser

Blood (2013) 122 (21): 4400.

https://doi.org/10.1182/blood.V122.21.4400.4400

Published: 2013

Journal Articles

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Michael Savona, MD, Martin Gutierrez, MD, Mark Lanasa, MD, PhD, Changchun Deng, MD, PhD, John Kuhn, PharmD, Lauren Sade, Hari Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Manish Patel, MD

Blood (2013) 122 (21): 4373.

https://doi.org/10.1182/blood.V122.21.4373.4373

Published: 2013

Journal Articles

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Ian Flinn, MD, PhD, Manish Patel, MD, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Yasuhiro Oki, MD, Pierluigi Porcu, MD, Jennifer Sweeney, BS, Kerstin Allen, MA, Kerrie Faia, MS, Patricia Harris, MPH, Joi Dunbar, PharmD, Howard M. Stern, M.D., Ph.D., Patrick Kelly, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 677.

https://doi.org/10.1182/blood.V122.21.677.677

Published: 2013

Journal Articles

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Joi Dunbar, PharmD, Jylle Nevejans, Charlotte McKee, MD, Kerrie Faia, MS, Jan Jaap van Lier, MD, Peter Pruim, MSc, Janet Stegehuis, PhD, Sue Zhao, MS, Brad S. Kahl, M.D., Steven M. Horwitz, MD, Manish Patel, MD, Anas Younes, MD, Ian W. Flinn, MD, PhD

Blood (2012) 120 (21): 4853.

https://doi.org/10.1182/blood.V120.21.4853.4853

Published: 2012

Journal Articles

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Chanan-Khan, MD, Manish Patel, MD, Kevin R. Kelly, MD, Kelli L. Running, Mary Murphy, Robin Guild, Christina Carrigan, PhD, Sharron Ladd, Beni B. Wolf, MD, PhD, James J. O'Leary, MD, Sikander Ailawadhi, MD

Blood (2012) 120 (21): 728.

https://doi.org/10.1182/blood.V120.21.728.728

Published: 2012

Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD

Blood (2012) 120 (21): 56.

https://doi.org/10.1182/blood.V120.21.56.56

Published: 2012

Journal Articles

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

Ian W. Flinn, MD, PhD, Steven M. Horwitz, MD, Manish Patel, MD, Anas Younes, MD, James R. Porter, PhD, Jennifer Sweeney, Kerstin Allen, MA, Patrick Kelly, MD, Brad S. Kahl, M.D.

Blood (2012) 120 (21): 3663.

https://doi.org/10.1182/blood.V120.21.3663.3663

Published: 2012

NARROW

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only